First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement

RNA interference (RNAi) is a potent and specific mechanism for regulating gene expression. Harnessing RNAi to silence genes involved in disease holds promise for the development of a new class of therapeutics. Delivery is key to realizing the potential of RNAi, and lipid nanoparticles (LNP) have pro...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer discovery 2013-04, Vol.3 (4), p.406-417
Hauptverfasser:	Tabernero, Josep, Shapiro, Geoffrey I, LoRusso, Patricia M, Cervantes, Andres, Schwartz, Gary K, Weiss, Glen J, Paz-Ares, Luis, Cho, Daniel C, Infante, Jeffrey R, Alsina, Maria, Gounder, Mrinal M, Falzone, Rick, Harrop, Jamie, White, Amy C Seila, Toudjarska, Iva, Bumcrot, David, Meyers, Rachel E, Hinkle, Gregory, Svrzikapa, Nenad, Hutabarat, Renta M, Clausen, Valerie A, Cehelsky, Jeffrey, Nochur, Saraswathy V, Gamba-Vitalo, Christina, Vaishnaw, Akshay K, Sah, Dinah W Y, Gollob, Jared A, Burris, 3rd, Howard A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Animals Cell Line, Tumor Cytokines - blood Female Humans Kinesin - genetics Liver Neoplasms - genetics Liver Neoplasms - metabolism Liver Neoplasms - therapy Male Mice Mice, SCID Middle Aged Nanoparticles - administration & dosage RNA Interference RNA, Messenger - metabolism RNA, Small Interfering - administration & dosage Vascular Endothelial Growth Factor A - genetics Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!